N4 Pharma Plc (AIM: N4P), provide details of its work plan following the encouraging data from its oncology research as announced on 13 December 2021. The company sounded very positive with the update released this week.
Share talk spoke with Nigel Theobald, covering the latest announcement and asking him about the market response to news being released by the company, current share price and how often do they have to update the markets?
Have you fully funded all current work streams in Q1/2 in 2022, yes we have more than sufficient funds to carry out the work planned, just a few of the topics raised in the podcast.
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
Listen On
Also Listen
-
Zak Mir talks to Rick Guiney, CEO of MicroSalt (AIM:SALT)
Zak Mir talks to Rick Guiney, CEO MicroSalt, after several recent bulk orders th -
Zak Mir talked to David Minchin, Chairman Helix Exploration
Today marked a pivotal moment for Helix Exploration as they announced a signific -
Zak Mir talks to Graham Lyon, Executive Chairman, Sound Energy
Zak Mir talks to Graham Lyon, Executive Chairman, Sound Energy as the transition -
HeLIX Exploration PLC Chairman David Minchin talking with Zak Mir
Zak Mir talks to David Minchin, Chairman Helix Exploration in the wake of the la